Mole Removal in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients with a mole exhibiting one or more ABCDE warning signs (Asymmetry, Border irregularity, Colour variegation, Diameter >6 mm, Evolution/change over time)

• Individuals with dysplastic (Clark's) nevi confirmed on dermoscopy or prior biopsy, particularly those with a personal or family history of melanoma

• Patients with congenital melanocytic nevi, especially giant congenital nevi (GCN >20 cm), which carry a lifetime melanoma transformation risk of 5–10%

• Cosmetically bothersome raised, pigmented, or repeatedly traumatised moles causing physical discomfort (e.g., snagging on clothing, recurrent bleeding)

• Patients with multiple atypical mole syndrome (Familial Atypical Multiple Mole and Melanoma syndrome, FAMMM) requiring surveillance excision

• Patients who have had a prior incomplete excision (positive histological margins) requiring re-excision

• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:

• Polarised-light dermoscopy (mandatory first-line triage tool; replaces need for blind excision in most cases)

• Total-body photography (TBP) or mole mapping — recommended for patients with >50 nevi or personal/family history of melanoma

• Reflectance confocal microscopy (RCM) or optical coherence tomography (OCT) — for lesions in cosmetically sensitive areas where excision would cause significant scarring and non-invasive rule-out of melanoma is desired

• Punch biopsy with histopathology + immunohistochemistry (HMB-45, Melan-A, S-100, Ki-67) — for ambiguous lesions prior to planning definitive excision margins

• Baseline blood tests (FBC, coagulation profile, fasting glucose) — required if general anaesthesia is planned

• Pregnancy test (urine or serum beta-hCG) — for women of childbearing age if sedation or GA is being considered

• RELATIVE CONTRAINDICATIONS:

• Active anticoagulant therapy (warfarin, apixaban, rivaroxaban) without haematology-approved bridging protocol — increases intraoperative bleeding risk

• Known keloid or hypertrophic scar tendency, especially for lesions on the chest, shoulders, or jaw — requires pre-counselling and modified technique

• Uncontrolled diabetes mellitus (HbA1c >9%) — impairs wound healing; optimisation required before elective excision

• Active skin infection or dermatitis in the operative field — procedure must be deferred until resolution

• Immunosuppressed patients (post-transplant, on biological therapy) — require infectious disease clearance; higher wound complication risk

• Lesions clinically suspicious for primary melanoma where sentinel lymph node biopsy (SLNB) planning is required — must be managed within a full melanoma MDT pathway, not as an isolated mole removal

STANDARD APPROACHES:

1. SURGICAL EXCISION WITH PRIMARY CLOSURE (Gold Standard for Atypical or Suspicious Nevi) The most oncologically sound method. Under local anaesthesia (1–2% lidocaine with 1:100,000 adrenaline), an elliptical excision is planned along Langer's lines of skin tension to ensure a cosmetically optimal scar orientation. Margins of 2 mm are used for clinically benign lesions; 5 mm for dysplastic nevi; and up to 1 cm for in situ melanoma (per NICE NG14 guidelines if malignancy is confirmed post-biopsy). Deep closure uses interrupted 3-0 or 4-0 absorbable Monocryl sutures to eliminate dead space and reduce wound tension; skin closure is with 5-0 or 6-0 Prolene or Ethilon, or alternatively Steri-Strip closure with tissue adhesive (Dermabond). Sutures are removed at 5–7 days (face) or 10–14 days (body). All specimens undergo formal histopathological review with margin assessment.

2. SHAVE EXCISION (For Raised, Benign, Intradermal Nevi) Using a DermaBlade or surgical scalpel angled at 15–30°, the raised portion of the mole is shaved flush with the surrounding skin surface. A shallow horizontal incision removes the bulk of the lesion without entering the deep dermis, minimising the risk of a linear scar. Haemostasis is achieved with aluminium chloride 20% solution or light electrocautery. This technique produces a flat, circular wound that heals by secondary intention over 2–4 weeks, typically with an excellent cosmetic result for dome-shaped intradermal nevi. Specimen histopathology is still mandatory to exclude unexpected dysplasia.

3. PUNCH EXCISION (For Small Nevi ≤6 mm) A circular punch biopsy tool (2–6 mm diameter) is used to core out small, well-defined moles in a single-step excise-and-biopsy procedure. The resulting circular defect is closed with 1–2 interrupted sutures or left to heal by secondary intention for very small defects. Punch excision offers speed, precision, and minimal surrounding tissue disturbance, making it ideal for facial nevi in areas such as the nasal tip or eyelid margin where tissue conservation is paramount.

4. CO2 LASER ABLATION AND Er:YAG LASER ABLATION (For Superficial, Benign Lesions in Cosmetically Sensitive Areas) Fractional CO2 laser (10,600 nm wavelength) or Er:YAG laser (2940 nm) vaporises melanocytic tissue layer-by-layer with minimal collateral thermal damage. CO2 laser offers simultaneous haemostasis; Er:YAG produces a cleaner ablation with faster healing. This approach is best reserved for clinically and dermoscopically confirmed benign flat or minimally raised moles where histopathological specimen retrieval is not the primary objective. It is not appropriate for any lesion with atypia, as no specimen is available for margin assessment. Downtime is 5–10 days of wound weeping and crusting.

5. RADIOFREQUENCY (RF) SHAVE REMOVAL High-frequency radiofrequency current (Surgitron or Ellman device, 3.8–4.0 MHz) allows bloodless, precise shave removal of raised nevi with simultaneous coagulation. The alternating current generates cellular heating causing tissue vaporisation without mechanical trauma. RF shave excision produces less thermal spread than electrocautery, resulting in superior cosmetic healing. Suitable for benign, raised nevi on the face, neck, and trunk; not indicated for suspicious or atypical lesions.

6. ADVANCED / RECONSTRUCTIVE APPROACHES (For Large or Facial Lesions) For large lesions (>2 cm) or nevi in cosmetically critical areas (nasal ala, lip, eyelid, ear), plastic surgeons employ local flap reconstruction (e.g., rhomboid flap, bilobed flap, Z-plasty, V-Y advancement flap) or full-thickness skin grafting (FTSG) to achieve primary closure without distorting adjacent anatomical structures. Giant congenital nevi may require staged tissue expander-assisted serial excision over multiple procedures. Intraoperatively, the CO2 laser may be used in combination with surgical excision to feather wound edges and improve final scar appearance.

7. MOHS MICROGRAPHIC SURGERY (For Lentigo Maligna / Melanoma In Situ on the Face) Where a mole excision reveals lentigo maligna or in situ melanoma in a cosmetically sensitive location, Mohs micrographic surgery — performed by a fellowship-trained Mohs surgeon — allows real-time, 100% margin assessment of the peripheral and deep margins using horizontal frozen sections. This tissue-sparing technique minimises the area of excision while ensuring complete histological clearance, and is endorsed by both NICE and the AAD for facial melanoma in situ.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel)

• Patient submits dermoscopic photographs or clinical images through GAF Healthcare's secure telemedicine portal for remote assessment by a board-certified dermatologist or plastic surgeon.

• The treating physician provides a provisional classification (benign vs. atypical vs. suspicious) and recommends the appropriate excision technique and required pre-op investigations.

• GAF Healthcare's medical coordinator prepares a detailed cost estimate, treatment plan, and coordinates e-Medical Visa documentation for India or UAE entry visa facilitation.

• Pre-operative blood work (FBC, coagulation screen, HbA1c if diabetic) may be performed at the patient's home country and uploaded digitally to reduce time spent in the destination country.

PHASE 2 — ARRIVAL & DAY-0 CONSULTATION

• GAF Healthcare airport representative meets the patient and accompanies them to partner accommodation or directly to the hospital for same-day admission if scheduled.

• In-person consultation with the operating surgeon: clinical examination, dermoscopy, photography, consent, and surgical plan finalisation.

• For patients requiring mole mapping or RCM, this is performed on Day 0 or Day 1 at the dermatology department.

• Anaesthetic review if IV sedation or general anaesthesia is planned (required for multiple lesion removal or anxious patients).

PHASE 3 — THE PROCEDURE (Day 1 or 2)

• The majority of mole removals are performed under local anaesthesia as a 15–45 minute outpatient procedure.

• Local anaesthetic (1% lidocaine with 1:100,000 epinephrine) is infiltrated around the lesion; 10–15 minutes are allowed for vasoconstriction to reduce intraoperative bleeding.

• Excision, shave, punch, or laser ablation is performed according to the pre-agreed technique.

• Wound closure (sutures, tissue adhesive, or dressing) is completed; the specimen is dispatched to the histopathology laboratory.

• Patient is discharged 1–2 hours post-procedure with wound care instructions, a 5-day course of topical antibiotic (mupirocin 2% or fusidic acid), and oral analgesics (paracetamol/ibuprofen — NSAIDs are typically adequate).

PHASE 4 — EARLY RECOVERY (Days 2–7)

• Day 2: First wound review by a nurse or surgeon; wound inspected for haematoma, seroma, or early infection signs; dressing changed.

• Days 3–5: Patients may experience mild erythema, swelling, and tenderness. No strenuous exercise or swimming. Wound kept dry for the first 48 hours.

• Day 5–7 (facial sutures): Suture removal performed by the clinical team; Steri-Strips applied for an additional 5–7 days to support wound edges.

• Histopathology results typically available within 5–7 working days; GAF Healthcare facilitates secure digital delivery of the pathology report to the patient and their home country physician.

PHASE 5 — PRE-DEPARTURE ASSESSMENT & FIT-TO-FLY CLEARANCE (Days 7–14)

• Surgeon conducts a formal wound review and confirms epithelialisation is complete and there is no active infection, haematoma, or wound dehiscence.

• Fit-to-fly letter is issued; patients are counselled on in-flight wound care (keep covered, avoid prolonged sun exposure during transit).

• Recommended flight time post-procedure: 5–7 days for laser/shave procedures; 10–14 days for sutured excisions involving large defects or flap reconstructions.

PHASE 6 — LONG-TERM FOLLOW-UP (Weeks 4–12 and Beyond)

• Scar maturation occurs over 3–12 months. Silicone gel (e.g., Kelo-cote, Dermatix) applied twice daily from Week 2 onwards for 3–6 months significantly improves final scar quality.

• Sun protection (SPF 50+) over the scar site is mandatory for 12 months to prevent post-inflammatory hyperpigmentation.

• Histopathology-confirmed dysplastic nevi: 6-monthly total-body skin examination recommended; GAF Healthcare coordinates telemedicine follow-up with the treating dermatologist.

• Recurrence (if it occurs) is typically identified within the first 12 months and managed with re-excision; GAF Healthcare's continuity-of-care protocol ensures patients can access their operative records from any country.